Human Genome Sciences Inc. Updates Albuferon Data
May 3, 2006
On Monday, Human Genome Sciences Inc. said a mid-stage drug trial of patients who had been previously treated for hepatitis C found that its candidate Albuferon, in combination with ribavirin, reduced the virus to undetectable levels in 31 percent (22 of 71 patients) of patients treated for 48 weeks. Twelve weeks after treatment ended, 20 percent (14 patients) maintained undetectable levels of virus. HGS plans to enter more advanced clinical trials by the end of this year.
Overlooked, Misunderstood and At-Risk: Exploring the Lives and HIV Risk of Ethnic Minority Male-to-Female Transgender Youth
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.